Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study
Shuyi Li,1 Mengke Niu,2 Wenying Deng,1 Ning Li,1 Chen Wei,1 Chi Zhang,1 Suxia Luo1 1Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, People’s Republic of China; 2Department of Oncology, Tongji Hospi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-12-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-of-chemotherapy-versus-transcatheter-arterial-chemoembolizati-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1818459869249798144 |
|---|---|
| author | Li S Niu M Deng W Li N Wei C Zhang C Luo S |
| author_facet | Li S Niu M Deng W Li N Wei C Zhang C Luo S |
| author_sort | Li S |
| collection | DOAJ |
| description | Shuyi Li,1 Mengke Niu,2 Wenying Deng,1 Ning Li,1 Chen Wei,1 Chi Zhang,1 Suxia Luo1 1Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, People’s Republic of China; 2Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, People’s Republic of ChinaCorrespondence: Suxia LuoDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, 450008, Henan Province, People’s Republic of ChinaTel +86 371 65587805Email zlyyluosuxia0361@zzu.edu.cnBackground: Primary hepatic neuroendocrine carcinoma (PHNEC) is a rare liver tumor, and there is no clear therapeutic recommendation for patients with advanced PHNEC. This study aims to compare the efficacy of platinum-based chemotherapy (etoposide combined with cisplatin/carboplatin, EP/EC) and transcatheter arterial chemoembolization (TACE) in patients with advanced PHNEC, and to evaluate the relevant prognostic factors.Patients and Methods: The clinical data of 41 patients with advanced PHNEC from June 2014 to October 2019 were retrospectively reviewed.Results: At a median follow-up time of 13.9 months, the median overall survival (OS) was 14.8 months in the EP/EC group and 12.2 months in the TACE group (P = 0.040). The median progression-free survival (PFS) was 4.4 months and 2.7 months in the EP/EC group and the TACE group, respectively (P = 0.005). No significant differences in the overall response rate and disease control rate were observed between the EP/EC group and the TACE group (26.1% vs 11.1%, P = 0.429; 73.9% vs 44.4%, P = 0.055, respectively). A univariate analysis indicated that the Eastern Cooperative Oncology Group performance status (ECOG PS), Ki-67, tumor number, and treatment options were prognostic factors for OS. A multivariate analysis further showed that ECOG PS (P < 0.001), Ki-67 (P = 0.003), and treatment options (P = 0.022) were independent prognostic factors for OS.Conclusion: Ki-67, ECOG PS, and treatment options were the independent prognostic factors for OS in patients with advanced PHNEC. EP/EC may be a better choice for patients with advanced PHNEC.Keywords: chemotherapy, transcatheter arterial chemoembolization, hepatic neuroendocrine carcinoma, prognosis |
| first_indexed | 2024-12-14T23:21:12Z |
| format | Article |
| id | doaj.art-439f9026729c4d129b54b01617a3f652 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-14T23:21:12Z |
| publishDate | 2021-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-439f9026729c4d129b54b01617a3f6522022-12-21T22:43:56ZengDove Medical PressCancer Management and Research1179-13222021-12-01Volume 139085909371361Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective StudyLi SNiu MDeng WLi NWei CZhang CLuo SShuyi Li,1 Mengke Niu,2 Wenying Deng,1 Ning Li,1 Chen Wei,1 Chi Zhang,1 Suxia Luo1 1Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, People’s Republic of China; 2Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, People’s Republic of ChinaCorrespondence: Suxia LuoDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, 450008, Henan Province, People’s Republic of ChinaTel +86 371 65587805Email zlyyluosuxia0361@zzu.edu.cnBackground: Primary hepatic neuroendocrine carcinoma (PHNEC) is a rare liver tumor, and there is no clear therapeutic recommendation for patients with advanced PHNEC. This study aims to compare the efficacy of platinum-based chemotherapy (etoposide combined with cisplatin/carboplatin, EP/EC) and transcatheter arterial chemoembolization (TACE) in patients with advanced PHNEC, and to evaluate the relevant prognostic factors.Patients and Methods: The clinical data of 41 patients with advanced PHNEC from June 2014 to October 2019 were retrospectively reviewed.Results: At a median follow-up time of 13.9 months, the median overall survival (OS) was 14.8 months in the EP/EC group and 12.2 months in the TACE group (P = 0.040). The median progression-free survival (PFS) was 4.4 months and 2.7 months in the EP/EC group and the TACE group, respectively (P = 0.005). No significant differences in the overall response rate and disease control rate were observed between the EP/EC group and the TACE group (26.1% vs 11.1%, P = 0.429; 73.9% vs 44.4%, P = 0.055, respectively). A univariate analysis indicated that the Eastern Cooperative Oncology Group performance status (ECOG PS), Ki-67, tumor number, and treatment options were prognostic factors for OS. A multivariate analysis further showed that ECOG PS (P < 0.001), Ki-67 (P = 0.003), and treatment options (P = 0.022) were independent prognostic factors for OS.Conclusion: Ki-67, ECOG PS, and treatment options were the independent prognostic factors for OS in patients with advanced PHNEC. EP/EC may be a better choice for patients with advanced PHNEC.Keywords: chemotherapy, transcatheter arterial chemoembolization, hepatic neuroendocrine carcinoma, prognosishttps://www.dovepress.com/efficacy-of-chemotherapy-versus-transcatheter-arterial-chemoembolizati-peer-reviewed-fulltext-article-CMARchemotherapytranscatheter arterial chemoembolizationhepatic neuroendocrine carcinomaprognosis |
| spellingShingle | Li S Niu M Deng W Li N Wei C Zhang C Luo S Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study Cancer Management and Research chemotherapy transcatheter arterial chemoembolization hepatic neuroendocrine carcinoma prognosis |
| title | Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study |
| title_full | Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study |
| title_fullStr | Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study |
| title_full_unstemmed | Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study |
| title_short | Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study |
| title_sort | efficacy of chemotherapy versus transcatheter arterial chemoembolization in patients with advanced primary hepatic neuroendocrine carcinoma and an analysis of the prognostic factors a retrospective study |
| topic | chemotherapy transcatheter arterial chemoembolization hepatic neuroendocrine carcinoma prognosis |
| url | https://www.dovepress.com/efficacy-of-chemotherapy-versus-transcatheter-arterial-chemoembolizati-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT lis efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy AT nium efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy AT dengw efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy AT lin efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy AT weic efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy AT zhangc efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy AT luos efficacyofchemotherapyversustranscatheterarterialchemoembolizationinpatientswithadvancedprimaryhepaticneuroendocrinecarcinomaandananalysisoftheprognosticfactorsaretrospectivestudy |